Diketoreductase mutant and application thereof
US10131883B2 · kind B2 · utility
0Cited by
0References
7Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Aug 4, 2014 |
| Grant date | Nov 20, 2018 |
| Priority date | — |
| Expiry date | Aug 4, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y101/01184
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The application provides a Diketoreductase (DKR) mutant, its nucleotide coding sequence, and an expression cassette, recombinant vector and host cell containing the sequence, as well as a method for application of the mutant to the preparation of 3R,5S-dicarbonyl compound. An ee value of the obtained 3R,5S-dicarbonyl compound is higher than 99%, and a de value is about 90%. The DKR mutant is a key pharmaceutical intermediate, and particularly provides an efficient catalyst for synthesis of a chiral dicarbonyl hexanoic acid chain of a statin drug.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.